The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

Podobne knjige/članki

• Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo
  od: Chen, Chun-Han, et al.
  Izdano: (2014)
• Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
  od: Chao, Min-Wu, et al.
  Izdano: (2019)
• Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib
  od: Tsai, A-C, et al.
  Izdano: (2014)
• In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells
  od: Tsai, An-Chi, et al.
  Izdano: (2014)
• Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI
  od: Cheong, Hio Teng, et al.
  Izdano: (2018)